<DOC>
	<DOCNO>NCT02701972</DOCNO>
	<brief_summary>The preclinical clinical evidence safety efficacy BACE device ( concept feasibility ) pave way evaluation BACE device prospective , multi-center , single-arm , self-controlled study safety efficacy treatment functional MR maximum 60 adult subject . The primary efficacy endpoint reduction MR grade 1+ less baseline MR grade 6 month study period . Primary safety endpoint freedom major device surgery-related adverse event duration 6 month follow period . Patients follow two year .</brief_summary>
	<brief_title>Evaluation Safety Efficacy BACEâ„¢ Device Treatment Functional Mitral Valve Regurgitation FMR</brief_title>
	<detailed_description>The primary objective study assess safety efficacy BACE device treatment FMR . Secondary objective ass ease deployment BACE device Study Population : Since study ass safety efficacy new device , control arm comparator , number subject enrol maximum 60 . Approximately 8-10 site expect included study . The subject population adult 18 80 year age , either gender , FMR specify inclusion exclusion criterion .</detailed_description>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Functional Mitral Valve Regurgitation ( FMR ) moderate severe grade ( 2 4 per American College Cardiology American Heart Association 2006 Classification Mitral regurgitation evaluation ) Symptomatic NYHA Class II IV Left Ventricular Ejection Fraction ( LVEF ) 25 % 50 % Normal mitral valve leaflet without abnormality damage Subject willing available return study followup Surgical approach treatment option Ability subject legal representative understand provide sign consent participate study Known hypersensitivity allergy device material History presence rheumatic heart disease Structural abnormality mitral valve ( e.g . flail leaflet , rupture elongated chordae , prolapse valve , perforate valve leaflet ) Severe pulmonary hypertension , define pulmonary artery systolic ( PAS ) pressure great equal 60 mm Hg Grade 4 diastolic dysfunction leave ventricle ECHO , change hemodynamic maneuver . ST segment [ electrocardiogram ] ( ST ) segment elevation myocardial infarction [ MI ] within 30 day enrollment study ; non ST segment elevation Myocardial Infarction ( MI ) within 7days enrollment study Currently enrol another investigational drug device study Subjects intraoperative [ correlate preop measurement end diastolic dimension ] heart circumference outside offer BACE device size range [ 21 41 cm ] Previous mitral valve surgery previous cardiac surgery would preclude proper placement BACE Abnormal coronary cardiac anatomy device could place without interfere anatomical structure Abnormalities mitral valve leaflet would necessitate mitral valve reconstruction replacement Prior Coronary Artery Bypass Graft ( CABG ) surgery Acute active infection Active peptic ulcer History IV drug abuse Chronic renal failure require dialysis Creatinine &gt; 2.5 mg/dl Open chest surgery contraindication [ e.g. , acute respiratory distress , endocarditis , myocarditis , pericarditis ] Immune suppression therapy include corticosteroid Subjects chronic connective tissue disease Investigator judgment body habitus sternal anatomy preclude pericardial access Females pregnant lactate Life expectancy &lt; 12 month due condition cardiac status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>